Sep 18, 2024 8:30am EDT Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
Sep 4, 2024 9:15am EDT Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series